• Study Design

TRODELVY

Study Design

TRODELVY WAS EVALUATED VS CHEMOTHERAPY IN 2L AND LATER mTNBC1,2

ASCENT: An international, Phase 3, multicentre, open-label, randomised study

*PFS was assessed by blinded independent central review based on RECIST 1.1 criteria in patients without brain metastases (n=468).1

ABBREVIATIONS:

2L, second line; BM-neg, brain metastases negative; ITT, intent-to-treat; IV, intravenous; mTNBC, metastatic triple-negative breast cancer; R, randomisation; RECIST, Response Evaluation Criteria in Solid Tumours;TNBC, triple-negative breast cancer; TROP-2, trophoblast cell surface antigen 2.

REFERENCES:

1. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics. June 2025. 2. Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541.